These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2581636)

  • 1. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system.
    Nicholson-Weller A; March JP; Rosen CE; Spicer DB; Austen KF
    Blood; 1985 May; 65(5):1237-44. PubMed ID: 2581636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria.
    Nicholson-Weller A; Spicer DB; Austen KF
    N Engl J Med; 1985 Apr; 312(17):1091-7. PubMed ID: 3845321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
    Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
    Kinoshita T; Medof ME; Silber R; Nussenzweig V
    J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.
    Carothers DJ; Hazra SV; Andreson SW; Medof ME
    J Clin Invest; 1990 Jan; 85(1):47-54. PubMed ID: 1688570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
    Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
    Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA).
    Ninomiya H; Abe T; Shichishima T; Terasawa T; Fujita T
    Br J Haematol; 1988 May; 69(1):81-7. PubMed ID: 2454648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of decay-accelerating factor and CD59 in lymphocyte subsets of healthy individuals and paroxysmal nocturnal hemoglobinuria patients.
    Nagakura S; Nakakuma H; Horikawa K; Hidaka M; Kagimoto T; Kawakita M; Tomita M; Takatsuki K
    Am J Hematol; 1993 May; 43(1):14-8. PubMed ID: 7686331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.
    Lederman MM; Purvis SF; Walter EI; Carey JT; Medof ME
    Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4205-9. PubMed ID: 2471198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation.
    Terstappen LW; Nguyen M; Lazarus HM; Medof ME
    J Leukoc Biol; 1992 Dec; 52(6):652-60. PubMed ID: 1281489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Medof ME; Kinoshita T; Silber R; Nussenzweig V
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo.
    Devine DV; Siegel RS; Rosse WF
    J Clin Invest; 1987 Jan; 79(1):131-7. PubMed ID: 2432087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
    Davitz MA; Low MG; Nussenzweig V
    J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
    Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.
    Moore JG; Frank MM; Müller-Eberhard HJ; Young NS
    J Exp Med; 1985 Oct; 162(4):1182-92. PubMed ID: 2413153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils.
    Kawakami Z; Ninomiya H; Tomiyama J; Abe T
    Br J Haematol; 1990 Apr; 74(4):508-13. PubMed ID: 1693286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.